Bovie Medical Corporation Announces Completion of Enrollment in J-Plasma®/RenuvionTM Dermal Resurfacing Study

Tuesday, May 15, 2018

Bovie Medical Corporation, a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the completion of enrollment for the U.S. Investigational Device Exemption (IDE) clinical study of its J-Plasma/Renuvion technology for use in dermal skin resurfacing.

“We are excited to announce that today we have enrolled the final patient in our dermal skin resurfacing study, which represents another important development in our strategy to build clinical support for our Renuvion technology and expand its clinical indications for use in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer. “We look forward to sharing the findings of this study, which we expect will provide support for our planned 510(k) submission to the U.S. Food and Drug Administration for an indication to market and sell J-Plasma/Renuvion for use in dermal resurfacing procedures.”

TOP